Alvotech re­sub­mits its in­ter­change­able Hu­mi­ra biosim­i­lar as Ab­b­Vie clings to brand dom­i­nance

Bil­lion­aire Alvotech CEO Róbert Wess­man told in­vestors on Thurs­day that the com­pa­ny has re­sub­mit­ted its Hu­mi­ra in­ter­change­able biosim­i­lar ap­pli­ca­tion to the FDA af­ter re­ceiv­ing a com­plete re­sponse let­ter due to man­u­fac­tur­ing is­sues last April.

While he did not dis­close a new user fee goal date yet, he sound­ed a pos­i­tive tone on im­prov­ing the man­u­fac­tur­ing de­fi­cien­cies at a Reyk­javík plant that led to the sec­ond CRL for the po­ten­tial in­ter­change­able biosim­i­lar, al­so known as AVT02.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER